Interim report Q1 2021
Interim report Q1 2021 Revenues amounted to MSEK 713.0 (793.6), corresponding to a decrease of -10% for the period. Revenues amounted to MSEK 713.0 ( 793.6), corresponding to a decrease of -10% for the period. The organic growth* during the first quarter was -16%. The currency impact in the quarter was -1% while the acquisitions of the product portfolios Proct from Leo Pharma and Pevaryl from Johnson & Johnson generated growth of +7%. EBIT (Operating Profit) amounted to MSEK 128.1 (104.1), corresponding to growth of 23%. EBITDA* amounted to MSEK 259.8 (209.3) corresponding to growth of 2...
Source: finanznachrichten.de